{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:57:00Z","timestamp":1785369420459,"version":"3.55.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.juro.2013.04.120","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T23:50:23Z","timestamp":1367970623000},"page":"1686-1691","source":"Crossref","is-referenced-by-count":40,"title":["Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Gu\u00e9rin Treatment Failure"],"prefix":"10.1097","volume":"190","author":[{"given":"Itay A.","family":"Sternberg","sequence":"first","affiliation":[{"name":"Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[{"name":"Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri M.","family":"Donat","sequence":"additional","affiliation":[{"name":"Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard H.","family":"Bochner","sequence":"additional","affiliation":[{"name":"Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry W.","family":"Herr","sequence":"additional","affiliation":[{"name":"Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2013.04.120_bib1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.120_bib2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.120_bib3","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.5489\/cuaj.1196","article-title":"The management of BCG failure in non-muscle-invasive bladder cancer: an update","volume":"3","author":"Zlotta","year":"2009","journal-title":"Can Urol Assoc J, suppl."},{"key":"10.1016\/j.juro.2013.04.120_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2013.04.120_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urolonc.2009.03.029","article-title":"Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG","volume":"28","author":"Barlow","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2013.04.120_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00345-011-0681-4","article-title":"Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy","volume":"29","author":"Yates","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2013.04.120_bib7","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A role for\u00a0neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2013.04.120_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3816\/CGC.2006.n.032","article-title":"Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer","volume":"5","author":"Jin","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.juro.2013.04.120_bib9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2013.04.120_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000071091","article-title":"Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation","volume":"71","author":"Meliani","year":"2003","journal-title":"Urol Int"},{"key":"10.1016\/j.juro.2013.04.120_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cncr.26238","article-title":"Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder","volume":"118","author":"Scosyrev","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2013.04.120_bib12","first-page":"CD008976","article-title":"Gemcitabine for unresectable, locally advanced or metastatic bladder cancer","volume":"4","author":"Shelley","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.juro.2013.04.120_bib13","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase\u00a0I\u00a0trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.04.120_bib14","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.04.120_bib15","series-title":"Textbook of Bladder Cancer","author":"Lerner","year":"2006"},{"key":"10.1016\/j.juro.2013.04.120_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","article-title":"Intravesical gemcitabine: a phase 1 and pharmacokinetic study","volume":"45","author":"Witjes","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.120_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.120_bib18","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.04.120_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2004.08.027","article-title":"Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions","volume":"65","author":"Serretta","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.04.120_bib20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.04.120_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study","volume":"56","author":"Bohle","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.04.120_bib22","doi-asserted-by":"crossref","unstructured":"Skinner EC, Goldman B, Sakr WA et\u00a0al: SWOG S0353: Phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG. Presented at annual meeting of\u00a0American Urological Association, Atlanta, Georgia, May 19-23, 2012, abstract 1666.","DOI":"10.1016\/j.juro.2012.02.1524"},{"key":"10.1016\/j.juro.2013.04.120_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713043097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713043097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2013.04.120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T03:35:59Z","timestamp":1651203359000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2013.04.120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1016\/j.juro.2013.04.120"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2013.04.120","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}